Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Solsona

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Actas Urologicas Espanolas|June 11, 2002
[Assessment of the basal membrane status as prognostic factor in renal carcinoma]J Rubio Briones, L Morell Quadreny, J A López Guerrero, et al.
Actas Urologicas Espanolas|January 25, 2011
[Immunohistochemical expression of microvascular density and carbonic anhidrase IX in renal carcinoma. Relation to histological type and tumoral progression]J Rubio-Briones, A Calatrava, A Fernández-Serra, et al.
Actas Urologicas Espanolas|March 12, 2014
Focal therapy for prostate cancer. Alternative treatmentF Gómez-Veiga, S Martínez-Breijo, E Solsona-Narbón, et al.
Actas Urologicas Espanolas|July 22, 2004
[Usefulness of serum markers in renal cell carcinoma]J Rubio Briones, I Iborra Juan, E Aznar, et al.
Actas Urologicas Espanolas|June 25, 2011
[Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer]J Rubio-Briones, A Fernández-Serra, M Ramírez, et al.
Actas Urologicas Espanolas|October 31, 2013
Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening programJ Rubio-Briones, J Casanova, R Dumont, et al.
BJU International|April 23, 2002
Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancerJ A Martínez-Piñeiro, N Flores, S Isorna, et al.
Actas Urologicas Espanolas|May 28, 2013
Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of UrologyH Villavicencio, C Hernández, A Gómez, et al.
British Journal of Cancer|June 1, 2013
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO studyC de la Piedra, A Alcaraz, J Bellmunt, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Actas Urologicas Espanolas|June 11, 2002
[Assessment of the basal membrane status as prognostic factor in renal carcinoma]J Rubio Briones, L Morell Quadreny, J A López Guerrero, et al.
Actas Urologicas Espanolas|January 25, 2011
[Immunohistochemical expression of microvascular density and carbonic anhidrase IX in renal carcinoma. Relation to histological type and tumoral progression]J Rubio-Briones, A Calatrava, A Fernández-Serra, et al.
Actas Urologicas Espanolas|March 12, 2014
Focal therapy for prostate cancer. Alternative treatmentF Gómez-Veiga, S Martínez-Breijo, E Solsona-Narbón, et al.
Actas Urologicas Espanolas|July 22, 2004
[Usefulness of serum markers in renal cell carcinoma]J Rubio Briones, I Iborra Juan, E Aznar, et al.
Actas Urologicas Espanolas|June 25, 2011
[Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer]J Rubio-Briones, A Fernández-Serra, M Ramírez, et al.
Actas Urologicas Espanolas|October 31, 2013
Optimizing prostate cancer screening; prospective randomized controlled study of the role of PSA and PCA3 testing in a sequential manner in an opportunistic screening programJ Rubio-Briones, J Casanova, R Dumont, et al.
BJU International|April 23, 2002
Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder cancerJ A Martínez-Piñeiro, N Flores, S Isorna, et al.
Actas Urologicas Espanolas|May 28, 2013
Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of UrologyH Villavicencio, C Hernández, A Gómez, et al.
British Journal of Cancer|June 1, 2013
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO studyC de la Piedra, A Alcaraz, J Bellmunt, et al.
Pageof 10